SCYNEXIS (SCYX) AI Stock Analysis

• Market Cap: $30.42M
• Dividend Yield: N/A
• Average Volume (3M): 612.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -65.77%
• EPS Growth: 38.61%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.17
• Shares Outstanding: 41,965,057
• 10 Day Avg. Volume: 689,890
• 30 Day Avg. Volume: 612,753
• PEG Ratio: 0.02
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 15.67
• P/FCF Ratio: -2.44
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 5.59
• Enterprise Value/Gross Profit: 5.59
• Enterprise Value/Ebitda: 7.63
• 1Y Price Target: $3.50
• Price Target Upside: 430.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.76 ▲(14.39% Upside)

The score is primarily held down by weak financial performance, driven by a steep revenue contraction, large losses, and significant negative free cash flow. Technicals are mixed with only modest short-term improvement and a weaker longer-term trend, while valuation is constrained by a negative P/E and no dividend yield data.

Positive Factors

Manageable leverage

A low absolute debt load versus equity reduces near-term refinancing pressure and preserves strategic optionality. For a small biotech, manageable leverage supports continued R&D and commercialization spending without immediate debt-servicing strain, lowering execution risk over months.

Sustained high gross margin

Persistently high gross margins imply the core product economics can support attractive unit-level profitability once sales scale. This structural margin buffer helps absorb commercial and R&D spend, improving long-term profitability prospects if revenue recovery occurs.

Niche antifungal franchise with unmet-need focus

A focused specialty antifungal pipeline targets high unmet medical need and drug-resistant infections, creating durable demand and potential pricing power. Niche positioning can yield regulatory exclusivity, favorable reimbursement, and partnership interest, supporting medium-term commercial prospects.

Negative Factors

Steep revenue collapse

A dramatic revenue decline severely erodes operating scale, weakens commercial credibility, and undermines fixed-cost leverage. Restoring durable revenue growth will require successful re-commercialization or new approvals; absent that, financial recovery and sustainable profitability remain uncertain for months.

Material negative cash flow

Large negative operating and free cash flows indicate ongoing cash burn that will necessitate external funding or meaningful cost reduction. This elevates dilution and financing risk, constrains investment in R&D and commercialization, and is a persistent execution challenge until cash flow turns positive.

Large losses and declining equity

Massive negative margins and falling equity reflect rapid deterioration in earnings quality and balance-sheet strength. Continued losses increase the probability of further capital raises, dilute shareholders, and limit the company's ability to self-fund growth initiatives absent a sustained operational turnaround.

SCYNEXIS Business Overview & Revenue Model

Company Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

How the Company Makes Money

SCYNEXIS generates revenue primarily through the commercialization of its products, which may include sales from its lead antifungal therapy once it receives regulatory approval. Additionally, the company may also earn revenue through partnerships and collaborations with other pharmaceutical companies for research and development purposes, as well as milestone payments and royalties from any licensed products. Grants and funding for research initiatives may also contribute to the company's overall revenue stream, particularly in the early stages of product development.

SCYNEXIS Financial Statement Overview

Summary

Financial fundamentals are weak: income statement and cash flow indicate a sharp deterioration versus 2023, with a major revenue drop, large losses, and significant ongoing cash burn. The balance sheet is comparatively better with low debt, but continued losses and declining equity elevate execution and funding risk.

Income Statement

Results have deteriorated sharply versus 2023. Revenue fell to ~$2.9M in TTM (Trailing-Twelve-Months) from $140.1M in 2023, and profitability swung from strong positive earnings in 2023 (net margin ~48%) to sizable losses in TTM (net margin ~-863%) and 2024 (net margin ~-568%). While gross margin remains high in recent periods, operating losses (negative EBIT margins) and the steep revenue contraction point to weak earnings quality and limited near-term visibility.

Balance Sheet

Leverage looks manageable in the latest period, with low total debt (~$2.3M) against equity (~$36.4M) in TTM (Trailing-Twelve-Months). The balance sheet also improved materially from 2022, when debt relative to equity was extremely elevated. However, ongoing losses are pressuring shareholder returns (negative return on equity in TTM and 2024), and the reduction in equity from 2024 to TTM suggests continued burn and/or valuation impacts.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow both negative in TTM (Trailing-Twelve-Months) (~-$33.6M) and 2024 (~-$24.0M), reversing the strong positive cash generation seen in 2023 (~$60.2M). The company is consuming cash to fund operations, and the cash outflow increased versus 2024, raising financing risk if losses persist. While free cash flow decline moderated versus prior years, the business is still firmly cash-flow negative in the most recent periods.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.93M	3.75M	140.14M	5.09M	13.16M	0.00
Gross Profit	2.93M	3.75M	124.52M	4.46M	12.85M	-303.00K
EBITDA	2.15M	-18.58M	70.89M	-59.91M	-32.91M	-55.65M
Net Income	-25.30M	-21.29M	67.04M	-62.81M	-32.87M	-55.19M
Balance Sheet
Total Assets	51.07M	90.64M	128.41M	87.81M	119.84M	102.54M
Cash, Cash Equivalents and Short-Term Investments	38.01M	59.30M	74.36M	73.50M	104.48M	93.04M
Total Debt	2.28M	16.27M	15.08M	48.60M	43.63M	19.84M
Total Liabilities	14.64M	35.57M	55.45M	84.58M	78.58M	79.78M
Stockholders Equity	36.43M	55.08M	72.96M	3.23M	41.26M	22.76M
Cash Flow
Free Cash Flow	-33.59M	-24.01M	60.16M	-79.89M	-55.73M	-49.36M
Operating Cash Flow	-33.59M	-24.01M	60.16M	-79.88M	-54.56M	-49.35M
Investing Cash Flow	33.51M	6.15M	-34.88M	-27.39M	-1.17M	6.47M
Financing Cash Flow	-14.21M	-139.00K	-36.72M	48.60M	67.12M	94.00M

SCYNEXIS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.66
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.67, and below the 200-day MA of 0.78, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 22.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.

SCYNEXIS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TXMD	52 Neutral	$26.04M	83.91	0.27%	―	75.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	51 Neutral	$58.93M	-15.40	-13.08%	―	12.21%	69.91%
SCYX	45 Neutral	$30.42M	-1.29	-53.29%	―	-65.77%	38.61%
AYTU	45 Neutral	$25.22M	-0.60	-50.23%	―	-15.61%	-68.96%
RMTI	42 Neutral	$40.59M	-6.27	-16.67%	―	-23.60%	-179.33%
IMCC	40 Underperform	$6.24M	-1.44	-93.87%	―	-0.74%	81.49%